<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1775">
  <stage>Registered</stage>
  <submitdate>10/12/2007</submitdate>
  <approvaldate>10/12/2007</approvaldate>
  <nctid>NCT00571467</nctid>
  <trial_identification>
    <studytitle>Phase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITP</studytitle>
    <scientifictitle>An Open Label, Sequential, Dose Escalation, Repeat-dose Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRTX-100 in Adult Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PRTX-100A-201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Idiopathic Thrombocytopenic Purpura (ITP)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PRTX-100 (Staphylococcal protein A)

Experimental: PRTX-100 (Staphylococcal protein A) - Cohort 1: 0.075 mcg/kg
Cohort 2: 0.15 mcg/kg
Cohort 3: 0.30 mcg/kg


Treatment: drugs: PRTX-100 (Staphylococcal protein A)
4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:
Cohort 1: 0.075 mcg/kg
Cohort 2: 0.15 mcg/kg
Cohort 3: 0.30 mcg/kg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluate the overall safety of PRTX-100 during the 3 month study duration</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Characterize the pharmacokinetics of multiple doses of PRTX-100</outcome>
      <timepoint>over the first 35 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Explore immunogenicity of multiple doses of PRTX-10</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate treatment effect on platelet count</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of chronic ITP &gt; 4 months

          -  Mean platelet count &lt;50 x 10^9/L for patients not receiving corticosteroids; or mean
             platelet count &gt;=50 x 10^9/L for patients receiving stable dose of corticosteroids</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Splenectomy within 45 days of screening

          -  Rituximab within 6 months prior to screening

          -  Cyclophosphamide, vincristine, or any other non-monoclonal antibody treatment for ITP
             within 3 months prior to screening

          -  IVIG, WinRho or other anti-RhD within 30 days prior to screening</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>9</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital - Garran</hospital>
    <hospital>St. George Hospital - Sydney</hospital>
    <hospital>Royal Brisbane - Brisbane</hospital>
    <hospital>Monash Medical Centre - Melbourne</hospital>
    <hospital>Freemantle Hospital - Freemantle</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode> - Garran</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Freemantle</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protalex, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of this study is to evaluate the safety of multiple doses of
      Staphylococcal protein A (PRTX-100) in adult patients with Idiopathic Thrombocytopenia
      Purpura (ITP). The pharmacokinetics, immunogenicity and pharmacodynamics will also be
      studied.

      Patients will be enrolled into 1 of 3 dose groups and receive 4 weekly IV doses of PRTX-100.
      A Safety Monitoring Committee will review safety data through Day 28 for the first 5 patients
      in a dose group before escalation to the next higher dose level. Patients will be followed
      for 8 weeks after dosing for safety, PK, immunogenicity and effect on platelet
      count(pharmacodynamics).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00571467</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edward Bernton, MD</name>
      <address>Protalex, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>